statistiche ricercatore

DE LERMA BARBARO, ANDREA

Distribuzione geografica

Continente	#
NA - Nord America	4.746
EU - Europa	4.716
AS - Asia	955
Continente sconosciuto - Info sul continente non disponibili	5
OC - Oceania	2
SA - Sud America	1
Totale	10.425

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	4.642
IT - Italia	2.481
UA - Ucraina	953
TR - Turchia	373
SE - Svezia	366
VN - Vietnam	328
FI - Finlandia	246
CN - Cina	222
DE - Germania	219
IE - Irlanda	204
CA - Canada	103
FR - Francia	100
GB - Regno Unito	98
IN - India	22
RU - Federazione Russa	11
BE - Belgio	10
NL - Olanda	9
CH - Svizzera	5
EU - Europa	5
JP - Giappone	5
AT - Austria	4
RS - Serbia	4
ES - Italia	2
NZ - Nuova Zelanda	2
AZ - Azerbaigian	1
CO - Colombia	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
GL - Groenlandia	1
GR - Grecia	1
PH - Filippine	1
PK - Pakistan	1
PL - Polonia	1
SG - Singapore	1
TW - Taiwan	1
Totale	10.425

Salva come PNG Salva come JPEG

Città	#
Milan	1.826
Jacksonville	723
Chandler	529
Fairfield	453
Woodbridge	354
Ashburn	290
Wilmington	257
Princeton	245
Ann Arbor	229
Izmir	229
Nyköping	216
Dublin	204
Dearborn	194
Seattle	188
Houston	167
Dong Ket	155
Cambridge	134
Rome	125
Como	100
Toronto	93
Beijing	92
San Mateo	92
New York	58
San Diego	55
Ogden	38
Düsseldorf	29
Verona	23
Pune	22
Hefei	20
Los Angeles	18
Boardman	15
Nanjing	15
London	13
Helsinki	12
Brussels	10
Guangzhou	10
Kunming	10
Norwalk	9
Jinan	8
Redwood City	8
Ponte Lambro	7
Washington	7
Auburn Hills	6
Rozzano	6
Villanova D'asti	6
Falls Church	5
Fuzhou	5
Vanzaghello	5
Zhengzhou	5
Belgrade	4
Casorezzo	4
Changsha	4
Hebei	4
Hounslow	4
Seveso	4
Voghera	4
Xian	4
Amsterdam	3
Chiswick	3
Costa Mesa	3
Edinburgh	3
Huzhou	3
Indiana	3
Nanchang	3
Ottawa	3
Phoenix	3
San Francisco	3
Shenyang	3
Tokyo	3
Varese	3
Wenzhou	3
Zurich	3
Chengdu	2
Chongqing	2
Frankfurt am Main	2
Graz	2
Magnago	2
Montreal	2
Monza	2
Muggiò	2
Prescot	2
Quzhou	2
Redmond	2
Rudolfstetten	2
Sesto San Giovanni	2
Simi Valley	2
Vienna	2
Wandsworth	2
West Jordan	2
Wuhan	2
Ürümqi	2
Acton	1
Atlanta	1
Auckland	1
Baku	1
Baotou	1
Bari	1
Berlin	1
Biella	1
Birmingham	1
Totale	7.444

Salva come PNG Salva come JPEG

Nome	#
Surface protein components from entomopathogenic nematodes and their symbiotic bacteria: effects on immune responses of the greater wax moth, Galleria mellonella (Lepidoptera: Pyralidae)	165
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human	157
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	155
The MHC class II transactivator: prey and hunter in infectious diseases	153
New strategies of mammary cancer vaccination	147
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	142
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	141
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	132
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	130
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review)	129
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	127
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	127
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	126
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.	124
In Vivo Effects of A Pro-PO System Inhibitor on the Phagocytosis of Xenorhabdus Nematophila in Galleria Mellonella Larvae	121
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	120
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2	120
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	118
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	111
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy	109
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	109
Therapy-induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan	108
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	107
MHC immunoevasins: protecting the pathogen reservoir in infection	106
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	106
Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules	102
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	102
PHYSIOLOGICAL TARGET OF THE AIR-1 TRANSACTIVATOR REVEALED BY STABLE TRANSFECTION ASSAY	101
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions	99
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells.	99
The complex liaison between cachexia and tumor burden	99
Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells	98
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	97
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	93
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan	91
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	91
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	90
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	90
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	88
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and partecipatine in the development of anti-inflammatory functional behavior of phagocytic macrophages	88
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class-II molecules combined with naked DNA interleukin-12 gene transfer	88
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	88
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy.	87
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene	86
The utility of introducing a measurement of tumor burden for a better assessment of cancer cachexia.	86
Irradiated CIITA-positive mammary adenocarcinoma cells act as potent anti-tumor preventive vaccine by inducine tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	85
CIITA reduced transcription as the cause of HLA class II downregulation in human macrophages during bacterial phagocytosis	84
Tumor rejection and anti-tumor memory to cancer cells of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. A new strategy of anti-tumor vaccination and tumor immunotherapy.	84
Regulation of HLA antigen expression in HIV infected cells	84
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down-modulation in normal human macrophages during bacterial phagocytosis	83
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity.	83
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	83
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy.	83
Analysis of microchimerism in thyroid autoimmune diseases	83
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	83
Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan	82
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	82
La presentazione antigenica su molecole di II classe HLA è profondamente alterata in seguito a fagocitosi batterica	81
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	81
The AIR-1 locus encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 replication by blocking the function of HIV-1 Tat	81
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	81
The complex liaison between vulnerability to cachexia and tumor burden.	81
Regolazione dell'espressione dei geni del Complesso Maggiore di Istocompatibilità HLA e di CD4 in cellule infettate da HIV: effetto di TAT	80
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	80
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	80
Imaging guided percutaneous microwave ablation of tumors.	77
Regulation of HLA antigen expression in phagocytes with mycobacteria	77
Higly stable oligomerization forms of HIV-1 Tat detected by Monoclonal antibodies and requirement of monomeric forms for the transactivating function of the HIV-1 LTR	76
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by gamma-IFN in promyelocytic cells	76
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	76
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down modulation in normal human macrophages during bacterial phagocytosis.	76
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	75
Induction of tumor regression by gene transfer of the MHC class II transactivator CIITA	74
HLA-DQ expression is differently regulated from -DR and -DP	73
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	73
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication	73
The molecular and cellular basis of tumor rejection after vaccination with mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	73
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA)	73
Irradiated CIITA-positive mammary adenocarcinoma cells act as effective tumor cell vaccine inducing both tumor-specific CD4+ and CD8+ T immune responses and tumor rejection upon challenge.	72
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	72
Tumor vaccination by CIITA-mediated MHC-II-expressing neoplastic cells	71
The replication of HTLV-2 and the expression of HLA class II transcriptional activator (CIITA) are inversely correlated	70
Constitutive and inducible expression of HLA class II genes in normal cells is under the control of the AIR-1-encoded CIITA trans-activator	70
HLA class II-dependent antigen presentation is deeply impaired in macrophage reservoir of infection	69
Temporal and quantitative relations between CIITA and HLA class II expression	69
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA	69
Regulation of HLA antigen expression in phagocytes treated with mycobacteria	69
Strong adaptive antitumor immune response elicited by targeting tumor necrosis factor a to tumor vessels in combination with melphalan.	68
The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells.	67
The immunological basis of tumor rejection and anti-tumor memory to neoplasias of different histotype genetically modified to express CIITA-driven autologous MHC class II genes.	67
Inibizione della replicazione virale di HIV-1 e HTLV-2 da parte di CIITA il regolatore trascrizionale dell'espressione dell'HLA-II	67
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	66
La fagocitosi di Mycobacterium Tuberculosis ha effetti opposti sull'espressione di superficie delle molecole HLA di classe I e di classe II	66
The AIR-1 locus-encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 productive infection by blocking the function of HIV-1 Tat	65
Reverse correlation between HTLV-II replication and expression of CIITA, the major regulator of HLA class II transcription	65
Non-replicating MHC Class II- CIITA-positive mammary adenocarcinoma cells act as an effective anti-tumor-preventive vaccine by inducing long-lasting tumor-specific CD8+ T cells and potent CD4+ T helper cells.	64
The immunological basis of therapy-induced antitumor vaccination by targeting Tumor Necrosis Factor a to tumor vessels in combination with melphalan	64
Induction of tumor rejection by gene transfer of the MHC class II transactivator CIITA	64
Innate and adaptive immune function of the MHC class II transactivator, CIITA, against human tumor retroviruses HTLV-2 and HTLV-1	64
Effetto del gene TAT di HIV sulla regolazione dell'espressione delle molecole HLA e CD4	64
Totale	9.151

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	32.062
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	32.062

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2018/2019	511	0	0	0	0	0	0	0	0	0	57	141	313
2019/2020	1.606	51	39	56	273	69	176	257	240	97	184	17	147
2020/2021	1.447	14	152	8	150	24	161	44	143	264	59	138	290
2021/2022	1.101	141	133	106	111	22	19	41	95	53	128	91	161
2022/2023	1.408	151	66	123	167	97	319	0	188	173	37	51	36
2023/2024	2.781	452	438	505	488	499	220	24	26	107	22	0	0
Totale													10.474